Xilio Therapeutics, Inc.
XLO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,344 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1,499 |
| Gross Profit | $6,344 | $0 | $0 | -$1,499 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $41,211 | $52,136 | $59,201 | $51,188 |
| G&A Expenses | $24,778 | $26,997 | $29,948 | $0 |
| SG&A Expenses | $24,778 | $26,997 | $29,948 | $22,357 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $937 | $0 | $0 | $0 |
| Operating Expenses | $66,926 | $79,133 | $89,149 | $73,545 |
| Operating Income | -$60,582 | -$79,133 | -$89,149 | -$75,044 |
| % Margin | -954.9% | – | – | – |
| Other Income/Exp. Net | $2,341 | $2,729 | $927 | -$756 |
| Pre-Tax Income | -$58,241 | -$76,404 | -$88,222 | -$75,800 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$58,241 | -$76,404 | -$88,222 | -$75,800 |
| % Margin | -918% | – | – | – |
| EPS | -1.09 | -2.78 | -3.19 | -2.72 |
| % Growth | 60.8% | 12.9% | -17.3% | – |
| EPS Diluted | -1.09 | -2.78 | -3.19 | -2.72 |
| Weighted Avg Shares Out | 53,511 | 27,496 | 27,392 | 27,358 |
| Weighted Avg Shares Out Dil | 53,511 | 27,496 | 27,392 | 27,358 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $100 | $0 | $0 | $600 |
| Depreciation & Amortization | $1,644 | $1,900 | $1,847 | $1,499 |
| EBITDA | -$58,001 | -$77,233 | -$87,302 | -$73,701 |
| % Margin | -914.3% | – | – | – |